Manhattan Bridge, New York City, USA

Discovering Drugs for Devastating Diseases

DISTINGUISHED LECTURE

Friday, September 30th, 2016
9:00 a.m.
NEOMED Institute (Saint-Laurent)

Registration is free. Please confirm your participation before September 19, 2016

Confirm my presence

Martin Mackay, PhD

Executive Vice President, Head of Research & Development
Alexion Pharmaceuticals

After years in big pharma, Dr. Martin Mackay moved to the biotech arena. He is currently the Executive Vice President, Head of Research &
Development at Alexion Pharmaceuticals, Inc. He leads the Research & Development organization in a range of disease areas (hematology,
nephrology, neurology, metabolic, transplant, and inflammatory disorders).

Prior to joining Alexion, Martin was the President of Research & Development at AstraZeneca Pharmaceuticals. Before that, Martin was the
President of PharmaTherapeutics Research & Development at Pfizer. His career at Pfizer spanned 15 years, where he held various leadership roles,
including the President of Research & Development. He also held roles at Ciba Pharmaceuticals and Beecham Pharmaceuticals.

He serves on the Scientific and Regulatory Committee of the industry trade group PhRMA and co-chairs the US-India BioPharma & Healthcare
Summit Advisory Board. Martin is a Visiting Professor at the University of Lincoln, UK.

An example of a success in applied and translational research in Montreal is the acquisition of Enobia Pharma by Alexion for $1.1 billion in 2011.
Enobia’s lead product, an enzyme-replacement therapy for patients suffering from hypophosphatasia, was originally developed at the Université de
Montréal’s Biochemistry laboratories through the work of Professor Philippe Crine.

A continental breakfast will be served at 8:15 a.m.

 

Registration is free. Please confirm your participation before September 19, 2016

Share this

Similar Events

© 2019 NEOMED Institute. All Rights Reserved. // Solutions Web Globalia